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Abstract 
In order to elucidate the molecular mechanisms responsible for the specific lipid-protein interactions, we have undertaken structural and idiotypic 
analyses of a monoclonal antibody, PS4A7, which binds specifically to phosphatidylserine (PS). Here we showed that one of the anti-idiotypic 
monoclonal antibodies raised against PS4A7 cross-reacted extensively with protein kinase C (PKC) and inhibited the activation of the enzymatic 
activity. The binding of the anti-idiotypic antibody to PKC was inhibited specifically by PS, but not by other phospholipids including 1,2-diacyl-sn- 
glycero-3-phospho-o-serine or 1,2-diacyl-sn-glycero-3-phospho-L-homoserine. In contrast, the binding of the anti-idiotypic mAb to the enzyme was 
significantly enhanced in the presence of either diacylglycerol or sphingosine. These findings indicate that the PS-specific monoclonal antibody and 
PKC share a consensus tructure which IS responsible for the specific interaction with PS and both diacylglycerol and sphingosine may induce a similar 
conformational change which exposes the PS-specific binding site of the enzyme. 
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1. Introduction 
Phosphatidylserine (PS) is a major anionic lipid com- 
ponent of mammalian plasma membranes. Recent anal- 
yses have shown that PS contributes to many regulatory 
processes of biological responses. The well-known func- 
tions of PS are its ability to regulate the enzymatic activ- 
ity of PKC [l-9] and to promote blood coagulation [lO- 
121. Some other proteins have been shown to interact 
specifically with PS. Typical examples are amino- 
phospholipid translocase [ 131, synaptotagmin [141, ad- 
ducin [ 151, synapsin I [16], putative receptor molecules 
on cell surfaces [17-201 and PS-specific phospholipase 
[21]. Although these proteins are supposed to interact 
with PS through their specific binding sites, no informa- 
tion has been available about the molecular mechanisms 
underlying the specific lipid-protein interactions. 
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PKC is a family of PS-dependent kinases that binds to 
the plasma membrane in response to receptor-mediated 
generation of diacylglycerol and Ca” [l-3]. Membrane- 
association of PKC is mediated by the interaction with 
multiple acidic phospholipids in the presence of Ca’+, 
while the enzymatic activity displays the strict structural 
requirement for 1,2-diacyl-sn-glycerol-3-phospho-L- 
serine (PS) [4-71. Although these observations suggest 
the existence of specific binding site for PS, it has been 
very difficult to validate the presence of a PS-specific 
binding site on the PKC, since the enzyme interacts with 
multiple phospholipid molecules during activation [8,9]. 
In order to elucidate the molecular mechanisms re- 
sponsible for the specific lipid-protein interactions, we 
have undertaken structural and idiotypic analyses of 
monoclonal antibodies (mAbs), which show the strict 
specificity to a certain phospholipid [22-261. One mAb, 
named PS4A7, bound specifically to PS, and distin- 
guished the stereo-specific onfiguration of the serine 
residue in PS [22], showing a reactivity profile similar to 
that reported for the activation of PKC. This mAb is 
expected to provide valuable information about specific 
lipid-protein interactions and be a structural template 
for the production of an anti-idiotypic antibody which 
can cross-react with the cellular PS-binding molecules. 
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Our previous analyses have shown that polyclonal 
anti-idiotypic antibody raised against a PC-specific mAb 
cross-reacted extensively with a PC-specific lipid transfer 
protein from bovine liver, which supports the hypothesis 
that they share a consensus recognition site for PC, and 
that part of the anti-idiotypic antibody may carry the 
internal image of the PC molecule 11241. In this study we 
established a series of anti-idiotypic mAbs against the 
PS-specific mAb and studied the interaction between the 
anti-idiotypic mAb and PKC. 
2. Materials and methods 
2 1 Establishment of antr-idrotypic mAb 
The PS-specific mAb, PS4A7, was produced by the direct immuniza- 
tion of PS coated on acid-treated Salmonella minnesota into BALBlc 
mouse spleen as described previously [22]. The anti-idiotypic mAbs 
were produced by the method as described previously [27]. In brief. 
BALB/c mice were intraperitoneally immunized with 50 pg PS4A7- 
KLH conmgate m complete Freund’s adjuvant, and received an addi- 
tional 50 fig conjugate in incomplete Freund’s adjuvant 2 weeks later. 
Two weeks after the second injection, the mice received SO pg PS4A7- 
KLH conmgate in saline, and fusion with P3-X63-Ag.653 cells was 
performed 3 days later. Hybridomas were cultured in a synthetic me- 
dium (GIT medium, Nippon Seiyaku Co. Ltd., Osaka, Japan) without 
a serum supplement. The hybridoma supernatants were screened for 
antibodies that bound to PS4A7, but not to an unrelated IgM, K mAb 
(MOl) using an ELISA. Hybridomas that inhibited the bindmg of 
PS4A7 to PS were further selected and were cloned three times by 
limiting dilution. From three fusions, 34 anti-idiotypic mAbs against 
the combining site of PS4A7 were established. 
2.2. Birzdrng of unto-ldiotypic mAbs to PKC 
Three subspecies of PKC from rat brain were purified to homogene- 
ity as described previously 1281. The binding of anti-idiotypic mAbs to 
PKC was examined by ELISA ]27]. In brief, microtiter plates were 
coated with 50.~1 of the purified enzymes (1 pmglml in 10 mM Tris-HCI 
buffered saline (TBSI. DH 7.4. overnight at 4°C). and were blocked bv 
incubation with TBS cantoning 30 &g/ml bovine serum albumin (3% 
BSA-TBS) for 2 h at room temperature. After washing with TBS, the 
plates were incubated with various amounts of purified anti-idiotypic 
antibodies diluted with 1% BSA-TBS for 2 hr at room temperature. The 
anti-idiotypic antibodies bound were detected with biotinylated anti- 
mouse immunoglobulin and peroxidase-conjugated streptavidm 
(Zymed Laboratories). 
2.3. Inhrbition of the bindrng of anti-idiotypyrc mAb to PKC by various 
phospholipids 
The effect of various lipids on the bmding of the anti-idiotypic mAb 
to PKC was examined as follows. The dried lipid films containing 2.0 
pm01 of each lipids were swollen in 10 mM ~-~-hydroxyethylpiperax- 
ine-~-ethanesulfonic acid (HEPESI buffer. aH 7.4. containine 150 mM 
NaCl and was sonicated by the Branson Sonifier for IO mm at 0°C 
under the nitrogen flow. PKCa (1 &ml) was coated onto the microtiter 
plates and was preincubated with various concentrations of the lipid 
suspensions for I h at room temperature. Then the binding of the 
antt-idiotyptc antibody (2 ,&ml) to PKC was examined by ELlSA as 
described above. Various phospholipids and synthetic PS analogs were 
prepared as described previously [22]. Sphingosine from bovine brain 
and 1,2-dioleoylglycrol were purchased from Serdary Research Labo- 
ratories. Inc. (Ontario, Canada). 
2.4. Inhibition of the actlvatron of the enzymatic activity of PKC b} 
anti-idiotypic mAh 
Enzymatic activity of PKC was determined by measuring the incor- 
poration of ‘?P from [Y-~~P]ATP mto a synthetic substrate peptide 
(RKRTLRRL) as substrate [29]. The reaction mixture (in 75 ~1 of 50 
mM Tris-HCl buffer. pH 7.5) contains 1 mM Ca-acetate, 15 mM 
Mg-acetate, 2.5 mM dithiothreitol, 0.2 .&ml phorbol U-myristate 
13-acetate, 50 ,uM ATP. 0.25 ~Uci of [y-“P]ATP, and 0.01% Trrton 
X-100 mixed micelle containing 8 mol% of PS. After Incubation at 25°C 
for 15 mm, the reaction was stopped by addition of a solution (25 ~1) 
containing 0.1 M ATP, 0.1 M EDTA. Aliquots (75 ~1) were spotted 
onto Whatman P81 filter paper, washed by 5% acettc acid solution. and 
prepared for liquid scintillation counting [30]. In the inhibition assay, 
PKC (1 ng) was preincubated with various concentrations of the anti- 
idiotypic antibody for 60 min at 4°C and the residual enzymatic activity 
was measured as described above. 
3. Results and ~seu~ion 
A monoclonal antibody PS4A7 [22] binds to 1,2-dia- 
cyl-sn-glycero-3-phospho-t_-serine (PS) but neither to 
1,2-diacyl-sn-glycero-3-phospho-p-serine nor 1,2-diacyl- 
sn-glycero-phospho-L-homoserine, showing a similar 
phospholipid specificity to that observed in the activa- 
tion of PKC [5]. We choose this mAb as a potential 
structural template for the production of anti-idiotypic 
mAbs according to the method as described previously 
[27]. BALBlc mice were immunized with PS4A7 conju- 
gated to keyhole limpet hemocyanin and and the hybrid- 
oma sup~rnatants were screened for antibodies that 
bound to PS4A7 but not to MOI, an unrelated mouse 
IgM. In order to obtain anti-idiotypic mAbs directed 
against the combining site of PS4A7, the clones were 
further selected according to their ability to inhibit the 
binding of PS4A7 to PS. We established 34 anti-idiotypic 
mAbs against the combining site of PS4A7 from 3 fu- 
sions and then examined the reactivity of the anti- 
idiotypic mAbs to PKC. Three subspecies of PKC were 
purified to homogeneity and the binding of the anti- 
idiotypic mAbs to the plate-coated PKCs was examined 
by ELISA. Among the anti-idiotypic mAbs established. 
one named Id8F7 bound significantly to the three sub- 
species of PKC (Fig. I) and effectively inhibited the acti- 
2 
0 PKC-a 
l PKCif3 
5 2.5 1.25 0.6 0.3 0.15 
Amounts of antibody (kg/ml) 
Fig. 1. Binding of anti-idiotypic mAb Id8F7 to PKC. Three isoforms 
of purified PKC 2271 (I &ml) were coated onto microtiter plates and 
incubated with various amounts of Id8F7. The mAb bound were de- 
tected with blotinylated anti-mouse IgM (Zymed) and peroxidase-con- 
Jugated streptavtdm. 
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Fig. 2. Effect of Id8F7 on the activation of enzymatic activity of PKC. 
PKC (I ng) was preincubated with either Id8F7 or a control monoclo- 
nal antibody (anti-phospholipase A2) for 60 min at 4”C, then the 
enzymatic activity was measured. The anti-idiotypic mAb inhibited the 
activation of the enzymatic activity of the three subspecies of PKC 
equally, and the result obtained with PKCa is shown. 
vation of the enzymatic activity (Fig. 2). Neither Ca” 
nor EDTA had an appreciable effect on the binding of 
IdSF7 to PKC (data not shown). 
In order to study whether or not the recognition site 
of IdSF7 on PKC is related to the PS-binding site of the 
enzyme, we examined the effect of various lipids on the 
binding of Id8F7 to PKC. As shown in Fig. 3a, the 
binding of Id8F7 to PKC was specifically inhibited by 
PS, but not by other phospholipids such as phosphati- 
dylethanolamine, phosphatidylinositol and phosphati- 
dylcholine. The inhibitory activity of PS is strictly de- 
pendent on the structure of PS, since the synthetic PS 
analogs such as 1,2-diacyl-sn-glycero-%phospho-D- 
serine and 1,2-diacyl-sn-glycero-phospho-L-homoserine 
showed no significant inhibitory effect on the binding 
(Fig. 3b). The results clearly indicate that the anti- 
idiotypic mAb recognized a common structure between 
PS- specific mAb and PKC, which is involved in the 
specific interaction with PS. 
The functional consequences of the binding of anti- 
idiotypic mAb to the enzyme could be manifested as both 
selective inhibition and stimulation of the enzymatic ac- 
tivity. Many studies have shown that not all antibodies 
that bind to receptors trigger the effector function; some 
antibody may actually inhibit the action of ligand, as 
would an antagonist [31]. Since the antibody-combining 
site is larger than the small ligand such as PS, the inter- 
actions between the anti-idiotypic mAb and the enzyme 
may sterically inhibit the activation of the enzymatic 
activity of PKC. 
In contrast to PS, preincubation of PKC with either 
1,2-dioleoyl-glycerol or sphingosine remarkably en- 
hanced the binding of Id8F7 to PKC. (Fig. 4). The dia- 
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Fig. 3. Inhibition of the binding of anti-idiotypic mAb to PKC by P.S. 
Effect of natural phospholipids (a) and synthetic PS analogs (b) on the 
binding of Id8F7 to PKC was analyzed by ELBA. Purified protein 
kinsae C a (1 @g/ml) was coated onto the microtiter plates and was 
preincubated with various con~ntrations of phospholipid vesicles for 
1 h at room temperature. Then the Id8F7 (2 +ug/ml) was added to each 
well and Id8F7 bound was detected with biotinylated anti-mouse IgM 
and peroxidase-conjugated streptavidin. 
cylglycerol binding site has been mapped to the cystein 
rich regions in the Cl region [32] and the interaction with 
diacylglycerol was suggested to enhance the affinity of 
PKC for PS [7]. Although the concentrations of the lipids 
required for the enhancement of the binding was quite 
high compared to those required for the activation of the 
enzymatic activity 141, it is likely that the interaction of 
PKC with diacylgly~rol caused the conformational 
change of the enzyme to expose the specific binding site 
for PS and resulted in the enhanced binding of the anti- 
idiotypic antibody to the enzyme. Since sphingosine is a 
potent inhibitor of the diacylglycerol binding to PKC 
[33], sphingosine may interact with the same site in PKC, 
inducing a similar conformational change. It should be 
stressed here that the conformational change induced by 
sphingosine should be different in some sense from that 
induced by diacylglycerol, since sphingosine inhibits the 
enzymatic activity of PKC whereas diacylglycerol stimu- 
lates the activity. 
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Fig. 4. Effect of diacylglycerol and sphingosine on the binding of IdSF7 to PKC. Purified protein kinsae C u (1 &ml) was coated onto the microtiter 
plates and was preincubated with various concentrations of either sphingosine or 1,2-dioleoylglycerol f r 1 h at room temperature. Then the Id8F7 
(2 ,@ml) was added to each well and Id8F7 bound was detected with biotinylated anti-mouse IgM and peroxidase-conjugated streptavidin. 
Concerning the phospholipid-binding domain in 
PKC, Clark et al. [34] reported a sequence homology 
among the Ca2+-dependent phospholipid-binding pro- 
teins such as the cytosolic phospholipase A2 (cPLA2), 
GTPase activating protein (GAP) and PKC. The region 
was tentatively identified as a Ca2’-dependent phospho- 
lipid-binding (CaLB) domain, since an amino-terminal 
fragment of cPLA2 (140 amino acid residues), which 
contains the CaLB domain, translocates to natural mem- 
brane vesicle in the presence of Ca” [34,35]. The putative 
CaLB domain in PKC was located to the amino acid 
residues 186-238 [34] in the C2 domain. Recent analyses, 
however, have shown that the activities of PKC (6, E, 6, 
r, and q) which lack the C2 domain are not affected by 
Ca’+, while they still require PS for activation [36]. The 
observations uggest hat these PKC might have another 
recognition site for PS. In the present study, the binding 
of the anti-idiotypic mAb to PKC was not influenced at 
all by free Ca2’ or chelating agent such as EDTA, imply- 
ing that the anti-idiotypic mAb might recognize an addi- 
tional recognition site for PS. Our current studies are 
directed toward identifying the recognition site of the 
anti-idiotypic mAb in PKC. 
The present analyses using the anti-idiotypic antibody 
clearly demonstrated that the anti-idiotypic mAb recog- 
nized a consensus tructure between the PS-specific mAb 
and PKC, a structure which may be responsible for the 
specific interaction with PS. The observations indicated 
that there is a distinct and specific recognition site for PS 
on PKC. Our recent work showed that the Id8F7 also 
cross-reacted extensively with blood coagulation factor 
V and VIII, suggesting that the structure, which is 
recognized by the anti-idiotypic antibody, may form a 
consensus structural motif responsible for the specific 
interaction with PS (unpublished observation). The anti- 
idiotypic antibody will provide a useful tool to identify 
the PS-specific recognition site and also to purify the 
cellular PS-binding proteins which have been difficult to 
isolate by the conventional biochemical techniques. 
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